|
|
糖尿病肾病蛋白尿的治疗研究进展
|
Abstract:
糖尿病肾脏疾病(Diabetic Kidney Disease, DKD)是由糖尿病引起的慢性肾脏病，以进展性的蛋白尿和(或)肾小球滤过率下降为主要临床特征。蛋白尿有效的控制与DKD患者的预后关系密切。本文就该病的流行病学、危害、相关药物研究进展等方面进行了综述。
Diabetic Kidney Disease is chronic kidney disease caused by diabetes, with progressive proteinuria and decreased glomerular filtration rate as the main clinical features. Effective control of pro-teinuria is closely related to the prognosis of patients with DKD. In this paper, the epidemiology, hazard and research progress of related drugs were reviewed.
| [1] | Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 98, S1-S115.
https://doi.org/10.1016/j.kint.2020.06.019 |
| [2] | Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 99, S1-S87. https://doi.org/10.1016/j.kint.2020.11.003 |
| [3] | Keyzer, C.A., van Breda, G.F., Vervloet, M.G., et al. (2017) Effects of Vitamin D Receptor Activation and Dietary Sodium Re-striction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial. Journal of the American Society of Nephrology, 28, 1296-1305. https://doi.org/10.1681/ASN.2016040407 |
| [4] | Fujisaki, K., Tsuruya, K., Nakano, T., et al. (2014) Im-pact of Combined Losartan/Hydrochlorothiazide on Proteinuria in Patients with Chronic Kidney Disease and Hyperten-sion. Hypertension Research, 37, 993-998.
https://doi.org/10.1038/hr.2014.110 |
| [5] | Shavit, L., Lifschitz, M.D. and Epstein, M. (2012) Aldosterone Blockade and the Mineralocorticoid Receptor in the Management of Chronic Kidney Disease: Current Concepts and Emerging Treatment Paradigms. Kidney International, 81, 955-968. https://doi.org/10.1038/ki.2011.505 |
| [6] | Kato, S., Maruyama, S., Makino, H., et al. (2015) Anti-Albuminuric Effects of Spironolactone in Patients with Type 2 Diabetic Nephropathy: A Multicenter, Randomized Clinical Trial. Clinical and Experimental Nephrology, 19, 1098- 1106. https://doi.org/10.1007/s10157-015-1106-2 |
| [7] | Tofte, N., Lindhardt, M., Adamova, K., et al. (2020) Early Detec-tion of Diabetic Kidney Disease by Urinary Proteomics and Subsequent Intervention with Spironolactone to Delay Pro-gression (Priority): A Prospective Observational Study and Embedded Randomised Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 8, 301-312.
https://doi.org/10.1016/S2213-8587(20)30026-7 |
| [8] | Mavrakanas, T.A., Gariani, K. and Martin, P.Y. (2014) Mineralocorticoid Receptor Blockade in Addition to Angiotensin Converting Enzyme Inhibitor or Angiotensin II Recep-tor Blocker Treatment: An Emerging Paradigm in Diabetic Nephropathy: A Systematic Review. European Journal of In-ternal Medicine, 25, 173-176.
https://doi.org/10.1016/j.ejim.2013.11.007 |
| [9] | Bakris, G.L., Agarwal, R., Chan, J.C., et al. (2015) Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial. JAMA, 314, 884-894. https://doi.org/10.1001/jama.2015.10081 |
| [10] | Bakris, G.L., Agarwal, R., Anker, S.D., et al. (2019) Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Dis-ease Trial. American Journal of Nephrology, 50, 333-344. https://doi.org/10.1159/000503713 |
| [11] | Bakris, G.L., Agarwal, R., Anker, S.D., et al. (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845 |
| [12] | Ann, J.F., Schmieder, R.E., McQueen, M., et al. (2008) Renal Outcomes with Telmisartan, Ramipril, or both, in People at High Vascular Risk (The ONTARGET Study): A Multicentre, Randomised, Double-Blind, Controlled Trial. The Lancet, 372, 547-553. https://doi.org/10.1016/S0140-6736(08)61236-2 |
| [13] | Clase, C.M. and Mann, J.F. (2014) Adding Lis-inopril to Losartan Increased Hyperkalemia and Acute Kidney Injury in Type 2 Diabetes and Proteinuria. Annals of Internal Medicine, 160, JC3.
https://doi.org/10.7326/0003-4819-160-6-201403180-02003 |
| [14] | Nathisuwan, S. and Talbert, R.L. (2002) A Re-view of Vasopeptidase Inhibitors: A New Modality in the Treatment of Hypertension and Chronic Heart Failure. Phar-macotherapy, 22, 27-42. https://doi.org/10.1592/phco.22.1.27.33502 |
| [15] | Feng, L., et al. (2012) LCZ696: A Du-al-Acting Sodium Supramolecular Complex. Tetrahedron Letters, 53, 275-276.
https://doi.org/10.1016/j.tetlet.2011.11.029 |
| [16] | Tersalvi, G., Dauw, J., Martens, P. and Mullens, W. (2020) Impact of Sacubitril-Valsartan on Markers of Glomerular Function. Current Heart Failure Reports, 17, 145-152. https://doi.org/10.1007/s11897-020-00463-1 |
| [17] | Mc Causland, F.R., Lefkowitz, M.P., Claggett, B., et al. (2020) Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction. Circulation, 142, 1236-1245.
https://doi.org/10.1161/CIRCULATIONAHA.120.047643 |
| [18] | Haynes, R., Judge, P.K., Staplin, N., et al. (2018) Effects of Sacubitril/Valsartan versus Irbesartan in Patients with Chronic Kidney Disease. Circulation, 138, 1505-1514. https://doi.org/10.1161/CIRCULATIONAHA.118.034818 |
| [19] | Kalra, S., Singh, V. and Nagrale, D. (2016) So-dium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Advances in Therapy, 33, 1502-1518. https://doi.org/10.1007/s12325-016-0379-5 |
| [20] | Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. (2016) Empagli-flozin and Progression of Kidney Disease in Type 2 Diabetes. The New England Journal of Medicine, 375, 323-334. https://doi.org/10.1056/NEJMoa1515920 |
| [21] | Neal, B., Perkovic, V., Mahaffey, K.W., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657. https://doi.org/10.1056/NEJMoa1611925 |
| [22] | IDF Diabetes Atlas, Ninth Edition 2019. https://www.diabetesatlas.org/en |
| [23] | Wiviott, S.D., Raz, I., Bonaca, M.P., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389 |
| [24] | Perkovic, V., Jardine, M.J., Neal, B., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744 |
| [25] | Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816 |
| [26] | 糖尿病肾脏疾病临床诊疗中国指南[J]. 中华肾脏病杂志, 2021, 37(3): 255-304. |
| [27] | Von Scholten, B.J., Persson, F., Rosenlund, S., et al. (2017) Effects of Liraglutide on Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes and Albuminuria: A Sub-Analysis of a Randomized, Placebo-Controlled, Double-Blind, Crossover Trial. Diabetes, Obesity and Metabolism, 19, 901-905. https://doi.org/10.1111/dom.12884 |
| [28] | Sinclair, A., Saeedi, P., Kaundal, A., et al. (2020) Diabetes and Global Ageing among 65-99 Year-Old Adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 162, Article ID: 108078. https://doi.org/10.1016/j.diabres.2020.108078 |
| [29] | Mann, J.F.E., ？rsted, D.D., Brown-Frandsen, K., et al. (2017) Liraglutide and Renal Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 377, 839-848. https://doi.org/10.1056/NEJMoa1616011 |
| [30] | Zhang, L., Long, J., Jiang, W., et al. (2016) Trends in Chronic Kidney Disease in China. The New England Journal of Medicine, 375, 905-906. https://doi.org/10.1056/NEJMc1602469 |
| [31] | Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (Rewind): A Double-Blind, Randomised Place-bo-Controlled Trial. The Lancet, 394, 121-130.
https://doi.org/10.1016/S0140-6736(19)31149-3 |
| [32] | (2019) Introduction: Standards of Medical Care in Diabetes-2019. Diabetes Care, 42, S1-S2. |
| [33] | Zhang, X.X., Kong, J. and Yun, K. (2020) Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies. Journal of Diabetes Re-search, 2020, Article ID: 2315607. https://doi.org/10.1155/2020/2315607 |
| [34] | 维生素D及其类似物在慢性肾脏病患者中应用的中国实践方案(2019版) [J]. 中华内科杂志, 2020, 59(2): 104-116. |
| [35] | 中国糖尿病肾脏疾病防治临床指南[J]. 中华糖尿病杂志, 2019(1): 15-28. |
| [36] | 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版) [J]. 中华肾脏病杂志, 2022, 38(5): 453-464. |
| [37] | Deng, X., Cheng, J. and Shen, M. (2016) Vitamin D Improves Diabetic Nephropathy in Rats by Inhibiting Renin and Relieving Oxidative Stress. Journal of Endocrinological Investigation, 39, 657-666.
https://doi.org/10.1007/s40618-015-0414-4 |
| [38] | Palmer, S.C. and Strippoli, G.F. (2013) Proteinuria: Does Vitamin D Treatment Improve Outcomes in CKD? Nature Reviews Nephrology, 9, 638-640. https://doi.org/10.1038/nrneph.2013.209 |
| [39] | Guo, K., Zhang, L., Zhao, F., et al. (2016) Prevalence of Chronic Kidney Disease and Associated Factors in Chinese Individuals with Type 2 Diabetes: Cross-Sectional Study. Journal of Diabetes and Its Complications, 30, 803-810.
https://doi.org/10.1016/j.jdiacomp.2016.03.020 |
| [40] | de Boer, I.H., Zelnick, L.R., Ruzinski, J., et al. (2019) Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients with Type 2 Diabetes: A Random-ized Clinical Trial. JAMA, 322, 1899-1909.
https://doi.org/10.1001/jama.2019.17380 |
| [41] | Pacilli, A., Viazzi, F., Fioretto, P., et al. (2017) Epidemiology of Diabetic Kidney Disease in Adult Patients with Type 1 Diabetes in Italy: The AMD-Annals Initiative. Diabe-tes/Metabolism Research and Reviews, 33, e2873.
https://doi.org/10.1002/dmrr.2873 |
| [42] | Looker, H.C., Mauer, M., Saulnier, P.J., et al. (2018) Changes in Albumi-nuria But Not GFR Are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 30, 1049-1059.
https://doi.org/10.1681/ASN.2018111166 |
| [43] | 孙玄静, 盛梅笑. 中医药治疗糖尿病肾病的机制研究[J]. 中国中西医结合肾病杂志, 2011, 12(12): 1117-1119. |
| [44] | Fox, C.S., Matsushita, K., Woodward, M., et al. (2012) Chronic Kidney Disease Prognosis Consortium. Associations of Kidney Disease Measures with Mortality and End-Stage Renal Disease in Individuals with and without Diabetes: A Meta-Analysis. The Lancet, 380, 1662-1673. https://doi.org/10.1016/S0140-6736(12)61350-6 |
| [45] | 徐慧, 刘万年, 徐启春. 中医辨证治疗慢性肾脏病蛋白尿的多中心前瞻性临床研究[J]. 中西医结合心血管病电子杂志, 2020, 8(13):169. |
| [46] | Matsushita, K., Coresh, J., Sang, Y., et al. (2015) CKD Prognosis Consortium. Estimated Glomerular Filtration Rate and Albuminuria for Prediction of Cardiovascular Outcomes: A Collaborative Meta-Analysis of Individual Participant Data. The Lancet Diabetes & Endocrinology, 3, 514-525. https://doi.org/10.1016/S2213-8587(15)00040-6 |
| [47] | Huang, W.J., Liu, W.J., Xiao, Y.H., et al. (2020) Tripterygium and Its Extracts for Diabetic Nephropathy: Efficacy and Pharmacological Mechanisms. Bio-medicine & Pharmacotherapy, 121, Article ID: 109599.
https://doi.org/10.1016/j.biopha.2019.109599 |
| [48] | Ninomiya, T., Perkovic, V., de Galan, B.E., et al. (2009) Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology, 20, 1813-1821.
https://doi.org/10.1681/ASN.2008121270 |
| [49] | Wang, D., Zhao, X.H., Cui, Y., et al. (2018) Efficacy and Safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A Systematic Review and Meta-Analysis. Phytotherapy Research, 32, 436-451.
https://doi.org/10.1002/ptr.5987 |
| [50] | Xu, L.N., et al. (2020) Tripterygium wilfordii Hook F Treatment for Stage IV Diabetic Nephropathy: Protocol for a Prospective, Randomized Controlled Trial. BioMed Research International, 2020, Article ID: 9181037.
https://doi.org/10.1155/2020/9181037 |
| [51] | Penno, G., Solini, A., Bonora, E., et al. (2018) Defining the Con-tribution of Chronic Kidney Disease to All-Cause Mortality in Patients with Type 2 Diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetologica, 55, 603-612. https://doi.org/10.1007/s00592-018-1133-z |
| [52] | 余江毅, 倪青, 刘苏. 糖尿病肾病病证结合诊疗指南[J]. 中医杂志, 2022, 63(2): 190-197. |
| [53] | Soejima, H., Ogawa, H., Morimoto, T., et al. (2020) Proteinuria Is Independently Associated with the Incidence of Primary Cardiovascular Events in Diabetic Patients. Journal of Cardiol-ogy, 75, 387-393.
https://doi.org/10.1016/j.jjcc.2019.08.021 |
| [54] | Heerspink, H.J., Kr？pelin, T.F., Hoekman, J., et al. (2015) Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. Journal of the American Society of Nephrology, 26, 2055-2064.
https://doi.org/10.1681/ASN.2014070688 |
| [55] | Burnier, M., Lin, S., Ruilope, L., et al. (2019) Effect of Angiotensin Receptor Blockers on Blood Pressure and Renal Function in Patients with Concomitant Hypertension and Chronic Kid-ney Disease: A Systematic Review and Meta- Analysis. Blood Pressure, 28, 358-374. https://doi.org/10.1080/08037051.2019.1644155 |
| [56] | 北京大学医学系糖尿病肾脏病专家共识协作组. 糖尿病肾脏病诊治专家共识[J]. 中华医学杂志, 2020, 100(4): 247-260. |
| [57] | 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6): 369-381. |
| [58] | Viazzi, F., Bonino, B., Cappadona, F., et al. (2016) Ren-in-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: Current Strategies and a Look Ahead. Internal and Emergency Medicine, 11, 627-635.
https://doi.org/10.1007/s11739-016-1435-5 |
| [59] | Brenner, B.M., Cooper, M.E., de Zeeuw, D., Ket al. (2001) Ef-fects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 345, 861-869.
https://doi.org/10.1056/NEJMoa011161 |
| [60] | Coleman, C.I., Weeda, E.R., Kharat, A., et al. (2020) Impact of Angi-otensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People with Type 2 Diabetes and Proteinuria. Diabetic Medicine, 37, 44-52. https://doi.org/10.1111/dme.14107 |
| [61] | Danta, C.C., Boa, A.N., Bhandari, S., et al. (2021) Recent Advances in Drug Discovery for Diabetic Kidney Disease. Expert Opinion on Drug Discovery, 16, 447-461. https://doi.org/10.1080/17460441.2021.1832077 |
